Skip to main content

Table 3 Multivariable logistic regression models evaluating change in radiographic score (change of 0 or >0) between baseline (< 2 years disease duration) and approximately 36-month disease duration visit in CLEAR I patients (N = 81)

From: Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans

Predictor/variable Odds ratio (adjusted)a 95 % CI P value
Multivariable model 1: anti-CCP
 Anti-CCP 2.73 (0.83, 9.0) 0.099
 RA disease duration (per 6 months) 0.90 (0.58, 1.38) 0.618
 Baseline radiographic score (0 referent to >0) 3.91 (1.38, 11.03) 0.010
 Smoking (reference to never smoker)
  Current 0.80 (0.25, 2.49) 0.695
  Former 0.67 (0.18, 2.45) 0.546
Multivariable model 2: anti-PAD4
 Anti-PAD4 0.59 (0.14, 2.51) 0.609
 RA disease duration (per 6 months) 0.87 (0.57, 1.33) 0.526
 Baseline radiographic score (0 referent to >0) 5.41 (1.97, 14.86) 0.001
 Smoking (reference to never smoker)
  Current 0.65 (0.21, 2.10) 0.478
  Former 0.60 (0.17, 2.20) 0.445
Multivariable model 3: anti-PAD4/PAD3
 Anti-PAD4/PAD3 0.21 (0.02, 2.76) 0.235
 RA disease duration (per 6 months) 0.87 (0.57, 1.35) 0.540
 Baseline radiographic score (0 referent to >0) 6.36 (2.22, 18.20) <0.001
 Smoking (reference to never smoker)
  Current 0.55 (0.18, 1.78) 0.319
  Former 0.51 (0.14, 1.89) 0.313
  1. RA medication and age were not significantly associated with the outcome in the bivariable model and therefore were not included in the multivariable models
  2. aAdjusted for all variables included in the table
  3. CLEAR Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis, CI confidence interval, RA rheumatoid arthritis, PAD peptidyl arginine deiminase enzyme
  4. P values less than 0.05 are shown in bold